WO2007132714A1 - Agent servant à accroître la densité osseuse - Google Patents

Agent servant à accroître la densité osseuse Download PDF

Info

Publication number
WO2007132714A1
WO2007132714A1 PCT/JP2007/059620 JP2007059620W WO2007132714A1 WO 2007132714 A1 WO2007132714 A1 WO 2007132714A1 JP 2007059620 W JP2007059620 W JP 2007059620W WO 2007132714 A1 WO2007132714 A1 WO 2007132714A1
Authority
WO
WIPO (PCT)
Prior art keywords
bone density
fatty acid
chain fatty
medium chain
bone
Prior art date
Application number
PCT/JP2007/059620
Other languages
English (en)
Japanese (ja)
Inventor
Katsuhiko Ooyama
Jian Wu
Michio Kasai
Keiichi Kojima
Original Assignee
The Nisshin Oillio Group, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Nisshin Oillio Group, Ltd. filed Critical The Nisshin Oillio Group, Ltd.
Priority to JP2008515501A priority Critical patent/JPWO2007132714A1/ja
Publication of WO2007132714A1 publication Critical patent/WO2007132714A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to foods and pharmaceutical compositions useful for the prevention and treatment of diseases associated with bone loss such as osteoporosis. More specifically, the present invention relates to a medium-chain fatty acid and / or medium-chain fatty acid, which can obtain effects such as an increase in bone density by ingesting the power of ingestion as it is or added to foods and pharmaceuticals.
  • the present invention relates to a bone density increasing agent containing acylglycerol, foods and drinks containing the same, and use in medicines.
  • Reduced bone density is due to osteoporosis, menopause, or hyperparathyroidism caused by steroid administration. It is found in many bone-related diseases, such as osteoporosis, secondary osteoporosis, and delayed bone formation due to gonadal dysfunction, causing fractures, bone deformation, pain, and dysfunction of organs and parts other than bone There is. As the aging population increases, there is a need to develop effective drugs that can cope with such a decrease in bone density, particularly drugs that increase bone density. The cause of decreased bone density is known to be related to a decrease in female hormones such as estrogen.
  • estrogen replacement therapy is performed in which estrogen such as estradiol is supplemented to prevent a decrease in bone density (see, for example, Patent Document 1).
  • this estrogen replacement therapy may have side effects such as uterine irregular bleeding and increase the risk of developing tumors such as cervical cancer or breast cancer. For this reason, attempts to use progesterone in combination with estrogen to reduce this side effect have not always produced satisfactory results (see, for example, Patent Document 2).
  • Non-patent Document 1 Protein 'energy malnutrition (Protein Energy Malnutrition; hereinafter abbreviated as “PE M”) is a serious clinical nutrition problem in various countries around the world (Non-patent Document 1). According to the 1990 WHO World Health Statistics, there are approximately 52 million people affected worldwide and 295,000 deaths per year. In Japan, 30 to 40% of nursing home residents nationwide suffer from PEM, which can be said to be the biggest nutrition problem for the elderly (Non-patent Document 2). People with serum albumin levels of 3.5 g / dl or less are diagnosed with PEM, and those who have a relative risk of death more than four times higher than non-PEM elderly after one year (Non-Patent Document 3) It is recognized as a serious disease.
  • PEM Protein 'energy malnutrition
  • the body protein pool In healthy adults, the difference between the amount of protein consumed and the amount of protein excreted outside the body, the so-called The nitrogen balance is approximately ⁇ 0, so the body protein pool is always constant. However, in some elderly people, the amount of ingested protein is less than the amount of excreted protein due to a number of factors such as decreased appetite, unfavorable taste, and decreased digestive absorption capacity associated with aging, resulting in a negative nitrogen balance. . In these individuals, the body protein pool tends to decrease over time, and the effects of this decrease include weight loss, muscle and visceral protein content, bone formation inhibition (Non-Patent Document 4), and serum albumin levels. As it manifests.
  • Patent Document 1 Japanese Patent Laid-Open No. 145024
  • Patent Document 2 JP-A-7-267858
  • Patent Document 3 Special Table 2001—519398
  • Non-patent document 1 Current significance of protein's energy nutrition disorder, “clinical nutrition” , 1999, 94 ⁇ , No. 3, 270 pages
  • Non-patent document 2 Nutrition management service for PEM improvement of the elderly, "Clinical nutrition”, Medical and Dental Publishers, 1999, 94 ⁇ , No. 4, p. 406
  • Non-Patent Document 3 Serum albumin level and physical disability as predictors of mortality in older persons. "JAMA”, USA, American Medical Association, 1994, 272, 13, No. 1036
  • Non-Patent Document 4 The effects oi recombinant human parathyroid hormon e, rhPTH (l-84), on bone mass in undernourished rats, Journal of Endocrinology, USA, Society for Endocrinology, 2002, 174 ⁇ , 419
  • Non-Patent Document 5 Complications of Bedridden Osteoporosis Patients, “Japanese Clinical”, Nippon Clinical Co., Ltd., 2004, 62 ⁇ , Zhou Zhi IJ 2, 655
  • Non-patent document 6 Protein nutritional disorder in the elderly, “Clinical nutrition”, Bio-Dental Publishing Co., Ltd., 1999, 94 ⁇ , No. 4, p. 401
  • the medium chain glyceride used in Patent Document 3 is an absorption promoter for Ca and Mg, which gives a synergistic effect on the bone resorption inhibitory action of bisphosphonate. It is only used and medium chain glycerides themselves are not used to improve bone density.
  • Medium-chain fatty acids and / or acyl-glycerols containing medium-chain fatty acids are directly transported to the liver via the portal vein where digestion and absorption are fast and are quickly decomposed into energy. It is characterized by being difficult to accumulate in fat cells that are easily consumed. For this reason, it is known that medium chain fatty acids and / or acyloglycerides containing medium chain fatty acids are useful for body fat reducing agents and the like, but there has been no report on bone density.
  • the present invention improves the bone density, thereby to osteoporosis, osteoporosis due to menopause or hyperparathyroidism, secondary osteoporosis, bone formation delay due to gonadal dysfunction, etc.
  • An object of the present invention is to provide a bone density increasing agent effective for the prevention and treatment of related diseases, specifically, a bone density increasing agent containing medium-chain fatty acid and / or acidoleglycerol containing medium-chain fatty acid as an active ingredient.
  • an object of the present invention is to provide foods and drinks, pharmaceuticals, etc. useful for the prevention and treatment of osteoporosis, fractures, etc., which have an effect of improving bone density.
  • medium chain fatty acids and / or a acylglycerol containing a medium chain fatty acid, preferably triacylglycerol whose constituent fatty acid consists only of a medium chain fatty acid hereinafter referred to as "medium chain fatty acid”
  • medium chain fatty acid fatty acid triglycerides
  • bone density increasing agent containing medium-chain fatty acid and / or acidoleglycerol containing medium-chain fatty acid in general foods, health foods, and functional foods, bone density can be improved. I found out that I can plan.
  • the present invention provides the following.
  • a bone density increasing agent containing as an active ingredient an acyloleglycerol containing a medium chain fatty acid and / or a medium chain fatty acid.
  • a medium-chain fatty acid and a acylglyceose containing Z or medium-chain fatty acid, preferably a medium-chain fatty acid triglyceride are administered to a rat in addition to a feed, as described later. Since the density is improved, it functions as a bone density increasing agent. This effect of increasing bone density is highly manifested in the distal femur, which is important for the prevention of osteoporosis (site that contains a lot of cancellous bone). It is also increased by combining exercise load
  • Osteoporosis and the like are diseases caused by bone resorption exceeding bone formation, bone mass, that is, bone density decreases and bone weakening occurs. By doing so, it is possible to prevent and improve bone-related diseases such as osteoporosis, secondary osteoporosis, and delayed bone formation due to gonadal dysfunction.
  • the fatty acid residue of the acylglycerol containing medium-chain fatty acid and / or medium-chain fatty acid has 6 to 12 carbon atoms, so that it is easily absorbed in the body. For this reason, the bone density increasing effect is more effectively performed.
  • the acyl glycerol containing the medium chain fatty acid is a medium chain fatty acid triglyceride
  • a bone density increasing agent according to 1) or (2) is provided.
  • the food and drink contain the bone density increasing agent, the bone density can be improved by daily intake of this food and drink. Therefore, bone-related diseases such as osteoporosis, secondary osteoporosis, and delayed bone formation due to gonadal dysfunction can be prevented and improved.
  • the medium chain fatty acid and Z or medium acid glycerol containing medium chain fatty acid contained in the bone density increasing agent of the present invention is easily consumed as energy, so that it does not accumulate in fat cells without the force S. Even if it is taken on a daily basis, it is difficult to accumulate as body fat. Therefore, even if taken continuously on a daily basis, there is little risk of becoming a lifestyle-related disease such as diabetes caused by the accumulation of body fat.
  • [0028] (7) Provided is a method of using a medium chain fatty acid and / or a acylglycerol containing a medium chain fatty acid to produce a bone density increasing agent.
  • Medium chain fatty acid and Z or medium chain fatty acid acylglycerol has the effect of increasing bone density as described above, and thus is used as a raw material for producing a bone density increasing agent.
  • an osteoporosis-preventing agent comprising a medium-chain fatty acid and Z or a acylglyceride containing a medium-chain fatty acid as effective components.
  • the medium chain fatty acid and / or the acylglycerol containing the medium chain fatty acid has the effect of increasing the bone density as described above.
  • the weakening of bones is prevented.
  • medium chain fatty acid and / or asinoleglycerol containing medium chain fatty acid is effective in preventing or treating osteoporosis.
  • medium chain fatty acid and Z or medium chain fatty acid acylglycerol has the effect of increasing bone density as described above, bones that have decreased due to inclusion in tablets, food and drink, etc. It can be used to increase the density or prevent the bone density from decreasing, and is used as a bone density increasing agent, osteoporosis preventing agent, or osteoporosis therapeutic agent.
  • the bone density increasing agent of the present invention has a bone density increasing action, it is not only taken as an easily ingested granule, but also can be easily ingested as a food or drink that is eaten on a daily basis. It is useful for the prevention or treatment of various bone diseases such as fractures, rheumatism, arthritis, low back pain, and osteoporosis, and is particularly useful for the treatment or prevention of osteoporosis in the elderly. It is highly effective in the treatment of diseases caused by calcium deficiency and low bone mass.
  • the active ingredient is a medium chain fatty acid and / or an acidoleglycerol containing a medium chain fatty acid, preferably a medium chain fatty acid triglyceride, which is easily absorbed into the body and is easily consumed as energy in the body. Since it is rarely accumulated in cells, it is difficult to accumulate as body fat even if it is taken on a daily basis.
  • the present invention relates to a bone density increasing agent comprising a medium chain fatty acid and / or a acyl glycerol containing a medium chain fatty acid, preferably a medium chain fatty acid triglyceride as an active ingredient.
  • Examples of preferred medium chain fatty acids contained in the bone mineral density increasing agent of the present invention include fatty acids having 6 to 12 carbon atoms such as n-hexanoic acid (cabronic acid), n- Examples include octanoic acid (caprinoleic acid), n-decanoic acid (capric acid), and lauric acid, and one or more of these can be used. Among these, saturated fatty acids having 8 to 10 carbon atoms, particularly n-octanoic acid and n-decanoic acid are preferable.
  • the method for producing the medium chain fatty acid used in the present invention is not particularly limited.
  • palm kernel oil or coconut oil containing medium chain fatty acid is hydrolyzed and then refined to obtain strength.
  • S can.
  • a commercial item and a reagent can also be used.
  • the acylglyceryl containing a medium chain fatty acid contained in the bone density increasing agent of the present invention is an ester of glycerin and a fatty acid, and at least one of the constituent fatty acids is an ester composed of a medium chain fatty acid.
  • monoacyldaricerol, diacylglycerol, and triacylglycerol can have one or more of these.
  • all of the constituent fatty acids may be medium-chain fatty acids, or long-chain fatty acids may be contained in addition to the medium-chain fatty acids.
  • the long chain fatty acid means a fatty acid having 14 or more carbon atoms.
  • triglyceryl glycerol is more preferable for acyl glycerol containing fatty acids and / or medium chain fatty acids. Among them, it is most preferable to use a medium chain fatty acid triglyceride in which all of the constituent fatty acids are medium chain fatty acids.
  • Medium chain triglycerides are generally referred to as MCT (Medium Chain Triglycerides), and the constituent fatty acids are triacylglycerols composed of fatty acids having 6 to 12 carbon atoms, preferably 8 to 10 carbon atoms. It is.
  • Medium-chain fatty acid triglycerides contain one type of fatty acid. Even if it is a constituent fatty acid, it may be a constituent fatty acid containing two or more kinds of fatty acids.
  • the constituent fatty acid is a medium-chain fatty acid triglyceride having one kind of fatty acid power
  • the fatty acid is preferably n-octanoic acid or n-decanoic acid.
  • the fatty acid is preferably n-octanoic acid and n-decanoic acid.
  • the mass ratio of n_octanoic acid and n_decanoic acid in all the constituent fatty acids is preferably a force S of 40Z60 to 90/10, more preferably a force of 60/40 to 85/15, Most preferred is 70 / 30-80 / 20.
  • the fatty acid constituting the acyl acylglycerol is methyl esterified.
  • Quantitative analysis can be performed by gas chromatography.
  • the method for producing acylglycol containing medium chain fatty acid used in the present invention is not particularly limited.
  • asinoleglycerol whose constituent fatty acid consists only of medium-chain fatty acids, is obtained by esterifying the medium-chain fatty acids obtained by hydrolysis of palm kernel oil and palm oil, followed by purification. Thereafter, it can be obtained by purification treatment.
  • the medium-chain fatty acid and / or acyl-glycerol containing the medium-chain fatty acid contained in the bone density increasing agent of the present invention has a good solubility in fats and oils, and therefore is suitably combined with fats and oils. Thus, an oil and fat composition can be obtained.
  • the oil / fat composition or processed oil / fat product is very preferable in terms of absorbability because it is expected to be absorbed together with the oil. Further, by increasing the amount of medium-chain fatty acid and Z or medium chain fatty acid-containing acylglycerol, it is possible to enjoy an extremely excellent increase in bone density.
  • the bone density increasing agent of the present invention has other physiological activities for the purpose of improving the function, in particular, synergistically improving the bone density increasing effect, assisting the bone density increasing effect, and improving the absorbability. It can be used in combination with components and the like.
  • physiologically active ingredients are not particularly limited as long as their physiological functions are clear, but for example, oily ingredients for improving the absorption in the body and increasing the efficiency of the effects, for nutritional enhancement Various vitamins, minerals, amino acids, and other physiologically active substances.
  • Oil components include soybean oil, rapeseed oil, oleic rapeseed oil, corn oil, sesame oil, sesame salad oil, perilla oil, linseed oil, peanut oil, safflower oil, safflower oil, safflower oil, sunflower oil, and high oleic acid Sunflower oil, cottonseed oil, grape seed oil, macadamia nut oil, hazelnut oil, cabotya seed oil, tarmi oil, coconut oil, tea seed oil, sesame oil, borage oil, olive oil, rice bran oil, wheat germ oil, beef fat, lard, chicken fat Fish oil, seal oil, algae oil, oils and fats that have been low-saturated due to quality improvement, hydrogenated oils and oils, fractionated oils and the like.
  • lignan As other physiologically active substances, for example, lignan, coenzyme Q, phospholipid, oryzanol and the like can be blended.
  • the bone density increasing agent comprising the medium chain fatty acid and / or the acyl chain glycerol containing the medium chain fatty acid as an active ingredient has the above-described bone density increasing effect. That is, by directly or indirectly taking the bone density increasing agent of the present invention, the bone density increasing effect can be enjoyed. Furthermore, it is possible to obtain a more favorable effect by taking it continuously.
  • the active ingredient means that it contains an amount that exhibits the effect of increasing bone density. Therefore, the content of the medium chain fatty acid and / or the acidoleglycerol containing the medium chain fatty acid in the bone density increasing agent of the present invention is not particularly limited as long as it is an amount that can exert the effect of increasing bone density. Depending on the intake and purpose of use, it may be adjusted as appropriate. However, if the effect is to be exerted with a small amount, it is preferable that the content is large. [0061]
  • the content of the medium chain fatty acid and / or the acino glycerol containing the medium chain fatty acid in the bone density increasing agent is preferably:! To 100% by mass, and is preferably 50 to 100% by mass. It is more preferred 70 ⁇ : 100% by mass is particularly preferred 80 ⁇ 100% by mass, particularly preferred.
  • the acylglycerone containing a medium chain fatty acid is a medium chain fatty acid triglyceride.
  • the above-described bone density increasing effect of the bone density increasing agent of the present invention can be obtained more remarkably when exercise is used in combination, as will be described in detail in Examples described later.
  • the maximum exercise intensity of the running exercise in the growing rat is about 40 m / min, and it can be said that this exercise intensity corresponds to human aerobic exercise. Therefore, according to the rat test results, it is possible to increase the bone density of humans by using exercise that is 40 to 60% of the maximum oxygen intake of healthy humans.
  • the amount of intake for obtaining a bone density increasing effect by taking the bone density increasing agent of the present invention varies depending on the form of intake, sex, body weight, physical condition, etc. of the subject and is particularly limited.
  • the intake amount as a medium chain fatty acid when a bone density increasing agent is ingested is most preferably 14 g / day or more.
  • the bone density increasing agent of the present invention is characterized by containing a medium chain fatty acid and / or a acyl glycerol containing a medium chain fatty acid, and includes a wide variety of foods and drinks such as fluid foods, health foods, infant foods, etc. Can be used in the field.
  • the bone density increasing agent of the present invention By blending the bone density increasing agent of the present invention into a food or drink as a raw material, a food or drink having an effect of increasing bone density can be obtained.
  • the form of the food for increasing bone density of the present invention is not particularly limited.
  • the food and drink are beverages, energy drinks, confectionery, processed foods, fats and oils, dairy products, retort foods, and range foods. Products, frozen foods, seasonings, health supplements, etc.
  • the shape and properties are not particularly limited and can be solid, semi-solid, gel, liquid, powder, etc. Any of capsules, liquids, granules, etc. may be used.
  • the food and drink for increasing bone density of the present invention may be blended with other physiologically active ingredients and the like for the purpose of improving various functions. Antioxidant ingredients, oily ingredients, various vitamins, minerals, amino acids, etc. for nutritional enhancement.
  • the antioxidant component is not particularly limited, but for example, tokovolols and their derivatives, tocotrienols and their derivatives, sesamin, epicesamine, sesaminol, sesamolin, sesamol and other lignans and their Glycosides, carotenoids such as ⁇ -carotene and their derivatives, tannins such as gallic acid ellagic acid and their derivatives, flavonoids such as flavone, catechin, quercetin, leucoanthocyanidin, ubiquinone, vitamin ⁇ , etc. Quinones, ferulic acid derivatives such as oryzanol, and olive extracts.
  • tokovolols and their derivatives tocotrienols and their derivatives
  • sesamin epicesamine
  • sesaminol sesamolin
  • sesamol and other lignans and their Glycosides carotenoids
  • tannins such as gallic acid ellagic acid and their derivatives
  • Power, fish and shellfish products such as maboko, chikuwa, hanpen, fish, dried fish such as shellfish, various species such as sea urchin, salmon, salmon, salted sea urchin, squid, etc.
  • Salmon products such as salmon, paste, small fish, shellfish, wild vegetables, shiitake mushrooms, kelp, etc., retort food such as curry and stew, miso, soy sauce, sauce , Ketchup, bouillon, grilled meat sauce, curry sauce, stew sauce, soup sauce, soup stock, various seasonings such as soup stock, cooked rice, oil and fat, margarine, shortening, mayonnaise, dressing and other processed fats and oils Range, frozen foods, etc. containing
  • processed oils and fats such as shortening, mayonnaise, dressing and the like are preferable.
  • shape and properties are not particularly limited, and any solid, semi-solid, gel, liquid, powder, etc. may be used.
  • Soft force Capsule, liquid, granule, etc. filled and processed into capsules and hard capsules may be used.
  • the bone density increasing agent of the present invention is an oily component, and therefore, part or all of the oily component in each food and drink is replaced with a bone density increasing agent. It is preferable to combine them.
  • edible oils and fats contain 95 to 100 mass%, margarine and shortening 70 to 80 mass%, mayonnaise 50 to 70 mass%, and dressing 10 to 30 mass% Can be made.
  • 5-20% by mass can be contained in bread and confectionery, and 5-20% by mass can be contained in beverages.
  • the indication that it is used for the prevention and improvement of osteoporosis is a notation that can be displayed mainly as a food for specified health use. For example, “a reduction in bone density is suppressed and osteoporosis is prevented. “To do it”, “To increase bone density and be healthy bones”, “Those who are concerned about osteoporosis”, and the like.
  • the indication that it is preferable to use in combination with exercise in the present invention is a notation that can be displayed mainly as food for specified health use. Examples include “Increase”, “Exercise after eating and drinking”, “If you want to increase bone density, exercise such as walking”.
  • Example 1 shows the bone density of the femur bone of a rat fed with a diet containing a bone density increasing agent (medium chain fatty acid triglyceride, Nisshin Oiliognolep Co., Ltd., trade name: ODO (registered trademark)),
  • a bone density increasing agent medium chain fatty acid triglyceride, Nisshin Oiliognolep Co., Ltd., trade name: ODO (registered trademark)
  • This was a test in which la and rapeseed oil (manufactured by Nissin Oilio Group Co., Ltd.) containing medium-chain fatty acids was compared as a control feed. Tests were sacrificed 6 weeks of feeding after rats, the excised femoral measured bone density in bone densitometry apparatus DCS- 600EX- IIIR (Alok a Inc.), was analyzed.
  • mice After 5-week-old Wistar male rats were preliminarily raised for 1 week, they were divided into 2 groups: a rapeseed oil-added group (control group) and a bone density increasing agent-added group. Experimental food and water based on AIN 93 standard feed (mass%) were given. During the test period, the body weight and food intake of rats were measured over time.
  • Example 2 is a study in which the effect of combined use of a bone density increasing agent and aerobic exercise on the bone density of growing rats was examined based on Example 1 described above.
  • Addition group (control group), medium-chain fatty acid triglyceride (Nisshin Oillio Group, product name: ODO (registered trademark)) addition group, divided into 8 groups each, Based on AIN93 standard diet containing 12% (mass%) of fats and oils, experimental diet and water were given.
  • a treadmill manufactured by Natsume Seisakusho Co., Ltd.
  • a running exercise of 45 minutes at a speed of 20 m / min was performed 5 days a week (Monday to Friday).
  • the maximum intensity of running in growing rats is approximately 40 m / min.
  • rats were allowed to run at a speed of 50% of their maximum exercise intensity, that is, at a speed of 20 m / min. It can be said that this exercise intensity corresponds to human aerobic exercise. Body weight and food consumption were measured over time, and exercise and rearing were conducted for 6 weeks.
  • Rats subjected to the test after 6 weeks were blood-collected under anesthesia with Nembutal (Dainippon Pharmaceutical Co., Ltd.) in the same manner as in Example 1, the femur of the hind limb was removed, and the soft tissue was removed.
  • the bone density of the femur was measured with a bone density measuring device.
  • the analysis includes the entire femur and the proximal part, Each bone density was calculated by dividing into a diaphyseal part and a distal part. The results are shown in Table 2.
  • Example 2 As described above, ingestion of the bone density increasing agent comprising medium-chain fatty acid triglyceride as an active ingredient from Example 1 and Example 2 has a positive effect on the bone growth of rats in the growth phase, and exercise is also used in combination. In this case, the bone density was further increased, suggesting the combined effect of both.
  • Example 3 is a verification test on the effect of the bone density increasing agent of the present invention on the bone density of human elderly PEM patients. Therefore, it should be performed on human PEM patients. However, PEM patients are weakened due to malnutrition and other reasons, and it is dangerous to allow such people to take new foods experimentally. In such a case, a method is generally used in which a disease model animal having symptoms similar to those of human PEM is prepared and evaluated using the animal.
  • a PEM model rat was prepared by feeding a rat with a low-protein diet containing the bone density increasing agent of the present invention, and the bone density of the rat was affected. The effect was investigated.
  • PEM model rats were produced by administering a low-protein diet (test food), which will be described in detail later. Serum serum in control rats after administration of test meal When the rubmin value was examined, it decreased by 21.8% compared to the rat before administration of the test meal, confirming that a PEM model rat was produced.
  • the BCG method was used as a method for measuring serum albumin levels.
  • the concentration of albumin is determined by measuring the blue absorbance of albumin and bromtalesol green (BCG) bound in a test tube using a spectrophotometer. Widely used for diagnosis.
  • rapeseed oil added group control group
  • bone density increasing agent medium chain fatty acid triglyceride, Nisshin Oiliognole Co., Ltd., trade name: ODO
  • the two groups were divided into 10 groups each, and feed and water having the composition shown in Table 3 were given.
  • the feed was based on the AIN93 standard feed, and the protein source casein was reduced from 20% to 5% by weight, and the amount was replaced with —starch.
  • there was no particular exercise load such as running exercise with a treadmill, and the animals were raised individually in stainless steel mesh cages and allowed to act freely.
  • Senorelose powder 5. 0 0 5. 0 0
  • Rapeseed oil 7. 0 0 0. 0 0
  • Bone density increasing agent 0. 0 ⁇ 7. 0 0
  • a ⁇ Port 4- ⁇ 1 0 0. 0 0 1 0 0. 0 0
  • Rats were sacrificed after 4 weeks of breeding, and the excised femur was measured using a bone densitometer DCS-600EX
  • the bone density was measured with the above-described bone density measuring apparatus.
  • the bone density was calculated by dividing the entire femur and the proximal, diaphyseal, and distal parts. The results are shown in Table 5.
  • the bone density increasing agent-added group showed a significant increase in bone density at all measured sites compared to the rapeseed oil added group. It was found that the increase was remarkable in the distal femur, which is an important site for prevention of the disease.
  • hypoalbuminemia which is a symptom of PEM
  • rapeseed oil vegetable oil

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un agent servant à accroître la densité osseuse qui peut accroître la densité osseuse et donc présenter des effets préventifs et thérapeutiques sur des maladies concernant les os telles que l'ostéoporose, l'ostéoporose provoquée par la ménopause ou l'hyperparathyroïdisme, l'ostéoporose secondaire ou l'ostéogenèse retardée provoquée par un dysfonctionnement gonadique. L'invention concerne plus précisément un agent servant à accroître la densité osseuse, ledit agent comprenant en tant qu'ingrédient actif un acide gras à chaîne moyenne et/ou un acylglycérol contenant un acide gras à chaîne moyenne. L'invention concerne également un aliment, une boisson, un médicament ou similaire qui présente un effet d'accroissement de la densité osseuse et qui est utile dans la prévention et le traitement de l'ostéoporose, d'une fracture osseuse et ainsi de suite. L'invention concerne plus précisément un agent servant à accroître la densité osseuse, ledit agent comprenant en tant qu'ingrédient actif un acide gras à chaîne moyenne et/ou un acylglycérol contenant un acide gras à chaîne moyenne. L'invention concerne également un aliment ou une boisson qui contient cet agent servant à accroître la densité osseuse et qui est utile dans la prévention ou le traitement de l'ostéoporose.
PCT/JP2007/059620 2006-05-16 2007-05-09 Agent servant à accroître la densité osseuse WO2007132714A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008515501A JPWO2007132714A1 (ja) 2006-05-16 2007-05-09 骨密度増加剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-136884 2006-05-16
JP2006136884 2006-05-16

Publications (1)

Publication Number Publication Date
WO2007132714A1 true WO2007132714A1 (fr) 2007-11-22

Family

ID=38693809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/059620 WO2007132714A1 (fr) 2006-05-16 2007-05-09 Agent servant à accroître la densité osseuse

Country Status (3)

Country Link
JP (1) JPWO2007132714A1 (fr)
TW (1) TW200812569A (fr)
WO (1) WO2007132714A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010052847A1 (fr) * 2008-11-06 2010-05-14 日清オイリオグループ株式会社 Régime alimentaire liquide concentré
JPWO2018207921A1 (ja) * 2017-05-12 2019-11-07 日清オイリオグループ株式会社 総ケトン体濃度上昇剤、油脂組成物、医薬組成物、食品組成物
CN114748462A (zh) * 2022-04-02 2022-07-15 浙江大学中原研究院 中链脂肪酸单甘油酯组合物在制备促进骨生长的产品中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04108360A (ja) * 1990-08-28 1992-04-09 Snow Brand Milk Prod Co Ltd カルシウム吸収促進栄養剤、食品及び飼料
JP2001519398A (ja) * 1997-10-10 2001-10-23 アストラゼネカ・アクチエボラーグ 骨粗鬆症の治療のための新規な改良された処方物
WO2004022051A1 (fr) * 2002-09-05 2004-03-18 The Nisshin Oillio Group, Ltd. Controleurs de recepteurs actives par proliferateur de peroxysome
JP2006062986A (ja) * 2004-08-25 2006-03-09 Api Co Ltd エストロゲン様作用剤及びその製造方法、並びに骨粗しょう症予防剤及び飲食品

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04253908A (ja) * 1990-12-28 1992-09-09 Nippon Oil & Fats Co Ltd 骨粗鬆症治療薬

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04108360A (ja) * 1990-08-28 1992-04-09 Snow Brand Milk Prod Co Ltd カルシウム吸収促進栄養剤、食品及び飼料
JP2001519398A (ja) * 1997-10-10 2001-10-23 アストラゼネカ・アクチエボラーグ 骨粗鬆症の治療のための新規な改良された処方物
WO2004022051A1 (fr) * 2002-09-05 2004-03-18 The Nisshin Oillio Group, Ltd. Controleurs de recepteurs actives par proliferateur de peroxysome
JP2006062986A (ja) * 2004-08-25 2006-03-09 Api Co Ltd エストロゲン様作用剤及びその製造方法、並びに骨粗しょう症予防剤及び飲食品

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SURENDRAN N. ET AL.: "Enhancement of calcium transport in the Caco-2 cell monolayer model", J. PHARM. SCI., vol. 84, no. 4, 1995, pages 410 - 414, XP000867843 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010052847A1 (fr) * 2008-11-06 2010-05-14 日清オイリオグループ株式会社 Régime alimentaire liquide concentré
JP5059947B2 (ja) * 2008-11-06 2012-10-31 日清オイリオグループ株式会社 濃厚流動食
US9907774B2 (en) 2008-11-06 2018-03-06 The Nisshin Oillio Group, Ltd. Concentrated liquid diet
US10285965B2 (en) 2008-11-06 2019-05-14 The Nisshin Oillio Group, Ltd. Method for supplementing and administering a concentrated liquid diet
US10383838B2 (en) 2008-11-06 2019-08-20 The Nisshin Oillio Group, Ltd. Concentrated liquid diet
JPWO2018207921A1 (ja) * 2017-05-12 2019-11-07 日清オイリオグループ株式会社 総ケトン体濃度上昇剤、油脂組成物、医薬組成物、食品組成物
CN114748462A (zh) * 2022-04-02 2022-07-15 浙江大学中原研究院 中链脂肪酸单甘油酯组合物在制备促进骨生长的产品中的应用
CN114748462B (zh) * 2022-04-02 2024-01-12 浙江大学中原研究院 中链脂肪酸单甘油酯组合物在制备促进骨生长的产品中的应用

Also Published As

Publication number Publication date
TW200812569A (en) 2008-03-16
JPWO2007132714A1 (ja) 2009-09-24

Similar Documents

Publication Publication Date Title
EP1430783B1 (fr) Composition huile/ matière grasse
CA2418350C (fr) Composition huile/matiere grasse
EP2247201B1 (fr) Produits alimentaires contenant des acides gras oméga-3
US20090156686A1 (en) Composition containing higher fatty acid derivative and foods and drinks
CN102065699A (zh) 含脂质组合物及其使用方法
WO2011077800A1 (fr) Agent permettant d'améliorer une hyperlipémie, composition permettant d'améliorer une anémie, composition permettant de réduire le taux d'acide urique et aliments et boissons
KR20110082052A (ko) 농후유동식
AU2006227949A1 (en) Composition and method for modulating hydrogen ion physiology
EP1481675A1 (fr) Agents destines a elever la temperature corporelle
EP2127663A1 (fr) Promoteur de production d'adiponectine
JP2009286703A (ja) Ｄ−タガトースを有効成分とする体脂肪蓄積改善剤およびメタボリックシンドローム改善剤
CN112399799A (zh) 脂肪蓄积抑制用组合物
CN101500424A (zh) 抑制年龄相关能力减退和食欲的佐餐补充剂
JP2013124221A (ja) 骨代謝改善剤
WO2007132714A1 (fr) Agent servant à accroître la densité osseuse
RU2386365C2 (ru) Применение производного сорбитана для предотвращения всасывания жиров
WO2015190682A1 (fr) Composition pour la promotion de la croissance contenant de l'acide coumarique comme principe actif
WO2019139032A1 (fr) Composition inhibant la perte musculaire pour patients atteints d'un cancer
JPWO2002094039A1 (ja) 蛋白質・エネルギー低栄養状態改善用飲食物
JP6596185B2 (ja) 総ケトン体濃度上昇剤、油脂組成物、医薬組成物、食品組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07743055

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008515501

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07743055

Country of ref document: EP

Kind code of ref document: A1